Haemophilus influenzae type b conjugate vaccines: a review of efficacy data
- 1 September 1998
- journal article
- review article
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 17 (9) , S117-S122
- https://doi.org/10.1097/00006454-199809001-00005
Abstract
The development of a vaccine against Haemophilus influenzae type b (Hib) was stimulated by its recognition as a major pathogen of early childhood. The first vaccine to be developed was composed of the capsular polysaccharide of the organism, polyribosylribitol phosphate (PRP), and although effective in older children, it failed to protect those To review the trials of Hib conjugate vaccines in which protective efficacy in infants has been assessed and the experience in countries in which Hib conjugate vaccines have been introduced into the routine infant immunization schedule. Each of the Hib conjugate vaccines [PRP-diphtheria toxoid conjugate (PRP-D), PRP conjugated to outer membrane protein of Neisseria meningitidis group B (PRP-OMP), PRP oligosaccharides conjugated to mutant diphtheria toxin CRM197, (HbOC) and PRP conjugated to tetanus toxoid (PRP-T)] has been subjected to prospective clinical trials and all have demonstrated high protective efficacy with one exception: that of the least immunogenic vaccine, PRP-D, when used in a Native American population with a high level of natural disease. The trials have used different populations and different schedules, which limits conclusions about relative efficacies. However, it seems likely that all the vaccines are capable of high efficacy in populations with low levels and late age of Hib disease. Three vaccines (PRP-D, PRP-OMP, PRP-T) have been tested in populations with high rates of disease and only PRP-D has been found lacking. As predicted by immunogenicity data, PRP-OMP affords efficacy after one dose, and PRP-T is efficacious with an accelerated schedule. Of more practical significance the effectiveness of these vaccines when introduced into populations has been uniformly impressive. Particularly where vaccine coverage is high, it is now likely that Hib disease can be eliminated using Hib conjugate vaccines in infancy.Keywords
This publication has 16 references indexed in Scilit:
- Efficacy of Haemophilus influenzae type b conjugate vaccine PRP-TThe Lancet, 1994
- Protection provided by Haemophilus influenzae type b conjugate vaccines in Los Angeles CountyThe Pediatric Infectious Disease Journal, 1994
- Invasive Haemophilus influenzae type b disease in the Oxford region (1985-91).Archives of Disease in Childhood, 1993
- Efficacy and safety of a Haemophilus influenzae type b capsular polysaccharide-tetanus protein conjugate vaccineThe Journal of Pediatrics, 1992
- Reduction of Oropharyngeal Carriage of Haemophilus influenzae Type b (Rib) in Children Immunized with an Rib Conjugate VaccineThe Journal of Infectious Diseases, 1991
- The Efficacy in Navajo Infants of a Conjugate Vaccine Consisting ofHaemophilus influenzaeType b Polysaccharide andNeisseria meningitidisOuter-Membrane Protein ComplexNew England Journal of Medicine, 1991
- Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61 080 childrenThe Pediatric Infectious Disease Journal, 1991
- Limited Efficacy of aHaemophilus influenzaeType b Conjugate Vaccine in Alaska Native InfantsNew England Journal of Medicine, 1990
- A Randomized, Prospective Field Trial of a Conjugate Vaccine in the Protection of Infants and Young Children against InvasiveHaemophilus influenzaeType b DiseaseNew England Journal of Medicine, 1990
- Efficacy ofHaemophilus IinfluenzaeType b Polysaccharide–Diphtheria Toxoid Conjugate Vaccine in InfancyNew England Journal of Medicine, 1987